Fernández, Joaquín
Rocha-de-Lossada, Carlos
Zamorano-Martín, Francisco
Rodríguez-Calvo-de-Mora, Marina
Rodríguez-Vallejo, Manuel
Funding for this research was provided by:
Johnson and Johnson (1316)
Article History
Received: 12 December 2022
Accepted: 6 March 2023
First Online: 14 March 2023
Declarations
:
: Scoping review does not involve human participants, therefore Ethics Committee approval was not required.
: Not applicable.
: Indaloftal SL (Qvision) received a research grant from Johnson & Johnson for the current study. Outside this work, Dr. Fernández is a consultant from Medicontur and has participated as a speaker in the activities of Oculus, Zeiss, and Bausch and Lomb. Remaining authors have nothing to disclose.